4741. Intermittent Occlusion of the Superior Vena Cava to Improve Hemodynamics in Patients With Acutely Decompensated Heart Failure: The VENUS-HF Early Feasibility Study.
作者: Navin K Kapur.;Michael S Kiernan.;Irakli Gorgoshvili.;Rayan Yousefzai.;Esther E Vorovich.;Ryan J Tedford.;Andrew J Sauer.;Jacob Abraham.;Charles D Resor.;Carey D Kimmelstiel.;Keith H Benzuly.;Daniel H Steinberg.;Julie Messer.;Daniel Burkhoff.;Richard H Karas.
来源: Circ Heart Fail. 2022年15卷2期e008934页
Reducing congestion remains a primary target of therapy for acutely decompensated heart failure. The VENUS-HF EFS (VENUS-Heart Failure Early Feasibility Study) is the first clinical trial testing intermittent occlusion of the superior vena cava with the preCARDIA system, a catheter mounted balloon and pump console, to improve decongestion in acutely decompensated heart failure.
4742. Genes That Escape X Chromosome Inactivation Modulate Sex Differences in Valve Myofibroblasts.
作者: Brian A Aguado.;Cierra J Walker.;Joseph C Grim.;Megan E Schroeder.;Dilara Batan.;Brandon J Vogt.;Andrea Gonzalez Rodriguez.;Jessica A Schwisow.;Karen S Moulton.;Robert M Weiss.;Donald D Heistad.;Leslie A Leinwand.;Kristi S Anseth.
来源: Circulation. 2022年145卷7期513-530页
Aortic valve stenosis is a sexually dimorphic disease, with women often presenting with sustained fibrosis and men with more extensive calcification. However, the intracellular molecular mechanisms that drive these clinically important sex differences remain underexplored.
4743. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.
作者: Joshua J Joseph.;Prakash Deedwania.;Tushar Acharya.;David Aguilar.;Deepak L Bhatt.;Deborah A Chyun.;Katherine E Di Palo.;Sherita H Golden.;Laurence S Sperling.; .
来源: Circulation. 2022年145卷9期e722-e759页
Cardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to substantial reductions in cardiovascular events. The 2015 American Heart Association and American Diabetes Association scientific statement, "Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence," highlighted the importance of modifying various risk factors responsible for cardiovascular disease in diabetes. At the time, there was limited evidence to suggest that glucose-lowering medications reduce the risk of cardiovascular events. At present, several large randomized controlled trials with newer antihyperglycemic agents have been completed, demonstrating cardiovascular safety and reduction in cardiovascular outcomes, including cardiovascular death, myocardial infarction, stroke, and heart failure. This AHA scientific statement update focuses on (1) the evidence and clinical utility of newer antihyperglycemic agents in improving glycemic control and reducing cardiovascular events in diabetes; (2) the impact of blood pressure control on cardiovascular events in diabetes; and (3) the role of newer lipid-lowering therapies in comprehensive cardiovascular risk management in adults with diabetes. This scientific statement addresses the continued importance of lifestyle interventions, pharmacological therapy, and surgical interventions to curb the epidemic of obesity and metabolic syndrome, important precursors of prediabetes, diabetes, and comorbid cardiovascular disease. Last, this scientific statement explores the critical importance of the social determinants of health and health equity in the continuum of care in diabetes and cardiovascular disease.
4744. Common Ancestry-Specific Ion Channel Variants Predispose to Drug-Induced Arrhythmias.
作者: Yuko Wada.;Tao Yang.;Christian M Shaffer.;Laura L Daniel.;Andrew M Glazer.;Giovanni E Davogustto.;Brandon D Lowery.;Eric H Farber-Eger.;Quinn S Wells.;Dan M Roden.
来源: Circulation. 2022年145卷4期299-308页
Multiple reports associate the cardiac sodium channel gene (SCN5A) variants S1103Y and R1193Q with type 3 congenital long QT syndrome and drug-induced long QT syndrome. These variants are too common in ancestral populations to be highly arrhythmogenic at baseline, however: S1103Y allele frequency is 8.1% in African Americans and R1193Q 6.1% in East Asians. R1193Q is known to increase late sodium current (INa-L) in cardiomyocytes derived from induced pluripotent stem cells but the role of these variants in modulating repolarization remains poorly understood.
4745. ZEB2 Shapes the Epigenetic Landscape of Atherosclerosis.
作者: Paul Cheng.;Robert C Wirka.;Lee Shoa Clarke.;Quanyi Zhao.;Ramendra Kundu.;Trieu Nguyen.;Surag Nair.;Disha Sharma.;Hyun-Jung Kim.;Huitong Shi.;Themistocles Assimes.;Juyong Brian Kim.;Anshul Kundaje.;Thomas Quertermous.
来源: Circulation. 2022年145卷6期469-485页
Smooth muscle cells (SMCs) transition into a number of different phenotypes during atherosclerosis, including those that resemble fibroblasts and chondrocytes, and make up the majority of cells in the atherosclerotic plaque. To better understand the epigenetic and transcriptional mechanisms that mediate these cell state changes, and how they relate to risk for coronary artery disease (CAD), we have investigated the causality and function of transcription factors at genome-wide associated loci.
4746. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
作者: Anthony P Carnicelli.;Hwanhee Hong.;Stuart J Connolly.;John Eikelboom.;Robert P Giugliano.;David A Morrow.;Manesh R Patel.;Lars Wallentin.;John H Alexander.;M Cecilia Bahit.;Alexander P Benz.;Erin A Bohula.;Tze-Fan Chao.;Leanne Dyal.;Michael Ezekowitz.;Keith A A Fox.;Baris Gencer.;Jonathan L Halperin.;Ziad Hijazi.;Stefan H Hohnloser.;Kaiyuan Hua.;Elaine Hylek.;Eri Toda Kato.;Julia Kuder.;Renato D Lopes.;Kenneth W Mahaffey.;Jonas Oldgren.;Jonathan P Piccini.;Christian T Ruff.;Jan Steffel.;Daniel Wojdyla.;Christopher B Granger.; .
来源: Circulation. 2022年145卷4期242-255页
Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data.
4747. Sex Differences in Factors Associated With Progression of Aortic Valve Calcification in the General Population.
作者: Axel Diederichsen.;Jes Sanddal Lindholt.;Jacob Eifer Møller.;Oke Gerke.;Lars Melholt Rasmussen.;Jordi S Dahl.
来源: Circ Cardiovasc Imaging. 2022年15卷1期e013165页
Guidelines recommend measurement of the aortic valve calcification (AVC) score to help differentiate between severe and nonsevere aortic stenosis, but a paucity exists in data about AVC in the general population. The aim of this study was to describe the natural history of AVC progression in the general population and to identify potential sex differences in factors associated with this progression rate.
4748. Myocardial Parametric Mapping by Cardiac Magnetic Resonance Imaging in Pediatric Cardiology and Congenital Heart Disease.
作者: Sruti Rao.;Stephanie Y Tseng.;Amol Pednekar.;Saira Siddiqui.;Murat Kocaoglu.;Munes Fares.;Sean M Lang.;Shelby Kutty.;Adam B Christopher.;Laura J Olivieri.;Michael D Taylor.;Tarek Alsaied.
来源: Circ Cardiovasc Imaging. 2022年15卷1期e012242页
Parametric mapping, that is, a pixel-wise map of magnetic relaxation parameters, expands the diagnostic potential of cardiac magnetic resonance by enabling quantification of myocardial tissue-specific magnetic relaxation on an absolute scale. Parametric mapping includes T1 mapping (native and postcontrast), T2 and T2* mapping, and extracellular volume measurements. The myocardial composition is altered in various disease states affecting its inherent magnetic properties and thus the myocardial relaxation times that can be directly quantified using parametric mapping. Parametric mapping helps in the diagnosis of nonfocal disease states and allows for longitudinal disease monitoring, evaluating therapeutic response (as in Thalassemia patients with iron overload undergoing chelation), and risk-stratification of certain diseases. In this review article, we describe various mapping techniques and their clinical utility in congenital heart disease. We will also review the available literature on normative values in children, the strengths, and weaknesses of these techniques. This review provides a starting point for pediatric cardiologists to understand and implement parametric mapping in their practice.
4749. Colchicine in Cardiovascular Disease: In-Depth Review.
作者: Spyridon G Deftereos.;Frans J Beerkens.;Binita Shah.;George Giannopoulos.;Dimitrios A Vrachatis.;Sotiria G Giotaki.;Gerasimos Siasos.;Johny Nicolas.;Clare Arnott.;Sanjay Patel.;Mark Parsons.;Jean-Claude Tardif.;Jason C Kovacic.;George D Dangas.
来源: Circulation. 2022年145卷1期61-78页
Inflammation plays a prominent role in the development of atherosclerosis and other cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular outcomes. For years, colchicine has been used as a safe and well-tolerated agent in diseases such as gout and familial Mediterranean fever. The widely available therapeutic has several anti-inflammatory effects, however, that have proven effective in a broad spectrum of cardiovascular diseases as well. It is considered standard-of-care therapy for pericarditis, and several clinical trials have evaluated its role in postoperative and postablation atrial fibrillation, postpericardiotomy syndrome, coronary artery disease, percutaneous coronary interventions, and cerebrovascular disease. We aim to summarize colchicine's pharmacodynamics and the mechanism behind its anti-inflammatory effect, outline thus far accumulated evidence on treatment with colchicine in cardiovascular disease, and present ongoing randomized clinical trials. We also emphasize real-world clinical implications that should be considered on the basis of the merits and limitations of completed trials. Altogether, colchicine's simplicity, low cost, and effectiveness may provide an important addition to other standard cardiovascular therapies. Ongoing studies will address complementary questions pertaining to the use of low-dose colchicine for the treatment of cardiovascular disease.
4755. First-in-Human Experience and Acute Procedural Outcomes Using a Novel Pulsed Field Ablation System: The PULSED AF Pilot Trial.
作者: Atul Verma.;Lucas Boersma.;David E Haines.;Andrea Natale.;Francis E Marchlinski.;Prashanthan Sanders.;Hugh Calkins.;Douglas L Packer.;John Hummel.;Birce Onal.;Sofi Rosen.;Karl-Heinz Kuck.;Gerhard Hindricks.;Bradley Wilsmore.
来源: Circ Arrhythm Electrophysiol. 2022年15卷1期e010168页
Pulsed field ablation (PFA) is a novel form of ablation using electrical fields to ablate cardiac tissue. There are only limited data assessing the feasibility and safety of this type of ablation in humans.
4757. Why Is Only Type 1 Electrocardiogram Diagnostic of Brugada Syndrome? Mechanistic Insights From Computer Modeling.
作者: Zhaoyang Zhang.;Peng-Sheng Chen.;James N Weiss.;Zhilin Qu.
来源: Circ Arrhythm Electrophysiol. 2022年15卷1期e010365页
Three types of characteristic ST-segment elevation are associated with Brugada syndrome but only type 1 is diagnostic. Why only type 1 ECG is diagnostic remains unanswered.
4758. Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations.
作者: Michael I Brener.;Amirali Masoumi.;Vivian G Ng.;Khodr Tello.;Marcelo B Bastos.;William K Cornwell.;Steven Hsu.;Ryan J Tedford.;Philipp Lurz.;Karl-Philipp Rommel.;Karl-Patrik Kresoja.;Sherif F Nagueh.;Manreet K Kanwar.;Navin K Kapur.;Gurumurthy Hiremath.;Mohammad Sarraf.;Antoon J M Van Den Enden.;Nicolas M Van Mieghem.;Paul M Heerdt.;Rebecca T Hahn.;Susheel K Kodali.;Gabriel T Sayer.;Nir Uriel.;Daniel Burkhoff.
来源: Circ Heart Fail. 2022年15卷1期e009101页
Right ventricular pressure-volume (PV) analysis characterizes ventricular systolic and diastolic properties independent of loading conditions like volume status and afterload. While long-considered the gold-standard method for quantifying myocardial chamber performance, it was traditionally only performed in highly specialized research settings. With recent advances in catheter technology and more sophisticated approaches to analyze PV data, it is now more commonly used in a variety of clinical and research settings. Herein, we review the basic techniques for PV loop measurement, analysis, and interpretation with the aim of providing readers with a deeper understanding of the strengths and limitations of PV analysis. In the second half of the review, we detail key scenarios in which right ventricular PV analysis has influenced our understanding of clinically relevant topics and where the technique can be applied to resolve additional areas of uncertainty. All told, PV analysis has an important role in advancing our understanding of right ventricular physiology and its contribution to cardiovascular function in health and disease.
4759. Response by Caravaca Pérez et al to Letter Regarding Article, "Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure".
作者: Pedro Caravaca Pérez.;Jorge Nuche.;Juan Carlos López-Azor.;Rafael Salguero-Bodes.;Fernando Arribas Ynsaurriaga.;Juan F Delgado.
来源: Circ Heart Fail. 2022年15卷1期e009258页 4760. Phrenic Nerve Injury During Cryoballoon-Based Pulmonary Vein Isolation: Results of the Worldwide YETI Registry.
作者: Christian-H Heeger.;Christian Sohns.;Alexander Pott.;Andreas Metzner.;Osamu Inaba.;Florian Straube.;Malte Kuniss.;Arash Aryana.;Shinsuke Miyazaki.;Serkan Cay.;Joachim R Ehrlich.;Ibrahim El-Battrawy.;Martin Martinek.;Ardan M Saguner.;Verena Tscholl.;Kivanc Yalin.;Evgeny Lyan.;Wilber Su.;Giorgi Papiashvili.;Maichel Sobhy Naguib Botros.;Alessio Gasperetti.;Riccardo Proietti.;Erik Wissner.;Daniel Scherr.;Masashi Kamioka.;Hisaki Makimoto.;Tsuyoshi Urushida.;Tolga Aksu.;Julian K R Chun.;Kudret Aytemir.;Ewa Jędrzejczyk-Patej.;Karl-Heinz Kuck.;Tillman Dahme.;Daniel Steven.;Philipp Sommer.;Roland Richard Tilz.
来源: Circ Arrhythm Electrophysiol. 2022年15卷1期e010516页
Cryoballoon-based pulmonary vein isolation (PVI) has emerged as an effective treatment for atrial fibrillation. The most frequent complication during cryoballoon-based PVI is phrenic nerve injury (PNI). However, data on PNI are scarce.
|